Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial

[1] Burgess TL(1999)The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts J Cell Biol 145 527-538

[2] Qian Y(2000)Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo Am J Pathol 157 435-448

[3] Kaufman S(1998)Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 93 165-176

[4] Ring BD(2000)Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function Endocrinology 141 3478-3484

[5] Van G(1998)Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL Proc Natl Acad Sci U S A 95 3597-3602

[6] Capparelli C(2003)Osteoclast differentiation and activation Nature 423 337-342

[7] Kelley M(2008)Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis Bone 43 92-100

[8] Hsu H(2003)Role of RANK ligand in mediating increased bone resorption in early postmenopausal women J Clin Invest 111 1221-1230

[9] Boyle WJ(2009)Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL J Bone Miner Res 24 182-195

[10] Dunstan CR(2007)Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low bone mineral density J Bone Miner Res 22 1832-1841

[1] Burgess TL(1999)The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts J Cell Biol 145 527-538

[2] Qian Y(2000)Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo Am J Pathol 157 435-448

[3] Kaufman S(1998)Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 93 165-176

[4] Ring BD(2000)Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function Endocrinology 141 3478-3484

[5] Van G(1998)Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL Proc Natl Acad Sci U S A 95 3597-3602

[6] Capparelli C(2003)Osteoclast differentiation and activation Nature 423 337-342

[7] Kelley M(2008)Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis Bone 43 92-100

[8] Hsu H(2003)Role of RANK ligand in mediating increased bone resorption in early postmenopausal women J Clin Invest 111 1221-1230

[9] Boyle WJ(2009)Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL J Bone Miner Res 24 182-195

[10] Dunstan CR(2007)Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low bone mineral density J Bone Miner Res 22 1832-1841